<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04240457</url>
  </required_header>
  <id_info>
    <org_study_id>330019</org_study_id>
    <nct_id>NCT04240457</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Corneal Crosslinking Using the PXL-Platinum 330 for Eyes With Corneal Ectatic Conditions</brief_title>
  <official_title>Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Crosslinking in Eyes With Corneal Ectatic Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbor Center for Eye Care</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arbor Center for Eye Care</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and effectiveness of the PXL Platinum 330 device for performing
      Corneal Crosslinking in patients with corneal thinning conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with progressive keratoconus, pellucid marginal degeneration, or at risk for
      post-refractive corneal ectasia will be recruited and undergo epithelial-on corneal
      crosslinking with the Peschke PXL-330 system using pulsed, accelerated energy delivery.
      Patients will undergo monitoring for 1 year, with serial measurements of corneal topography,
      visual acuity, intraocular pressure and visual function questionnaire assessments.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">February 2026</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Treatment of patients with disease</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Randomized at outset</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mean keratometry in diopters</measure>
    <time_frame>1 year</time_frame>
    <description>Average keratometry across the anterior topography of the cornea computed by a validated topographer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>1 year</time_frame>
    <description>Measurement of best corrected visual acuity on the validated early-treatment diabetic retinopathy study scale.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Keratoconus</condition>
  <condition>Cornea Ectasia</condition>
  <arm_group>
    <arm_group_label>Pulsed, accelerated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18mW, 5 seconds on, 5 seconds off, 10 minutes of illumination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>9mW continuous, 10 minutes of illumination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Epithelial-on Corneal Crosslinking with the PXL 330 Platinum system.</intervention_name>
    <description>PXL-330 Platinum device for crosslinking with Peschke riboflavin solution. Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea.</description>
    <arm_group_label>Conventional</arm_group_label>
    <arm_group_label>Pulsed, accelerated</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inclusion Criteria: Criterion 1,2,3 are required for all participants. Participants
             must also meet one or more of criteria 4-12 . Criterion 13 is relevant only for
             contact lens wearers

        Subjects who have one or both eyes that meet criteria 1 and one or more of the following
        criteria will be considered candidates for this study:

          1. 12 years of age or older

          2. Presence of central or inferior steepening.

          3. Axial topography consistent with keratoconus, post-surgical ectasia, or pellucid
             marginal degeneration

          4. Presence of one or more findings associated with keratoconus or pellucid marginal
             degeneration, such as:

               1. Fleischer ring

               2. Vogt's striae

               3. Decentered corneal apex

               4. Munson's sign

               5. Rizzutti's sign

               6. Apical Corneal scarring consistent with Bowman's breaks

               7. Scissoring of the retinoscopic reflex

               8. Crab-claw appearance on topography

          5. Steepest keratometry (Kmax) value â‰¥ 47.20 D

          6. I-S keratometry difference &gt; 1.5 D on the Pentacam map

          7. Posterior corneal elevation &gt;16 microns

          8. Thinnest corneal point &lt;485 microns

          9. Predicted Post LASIK/PRK stromal ablation depth &lt;350 microns or expected keratometry
             &gt;47.2 D, or patients undergoing PRK in keratoconus suspect eyes

         10. Contact Lens Wearers Only:

             a. Removal of contact lenses for the required period of time prior to the screening
             refraction:

         11. Signed written informed consent

         12. Willingness and ability to comply with schedule for follow-up visits

         13. Contact Lens Wearers Only:

               1. Removal of contact lenses for the required period of time prior to the screening
                  refraction:

        Contact Lens Type Minimum Discontinuation Time: Soft 1 Week, Soft Extended Wear 2 Weeks,
        Soft Toric 3 Weeks, Rigid Gas Permeable 2 Weeks per decade of wear

        Exclusion Criteria (any of the following are reasons for exclusion):

          1. Eyes classified as either normal or atypical normal on the severity grading scheme.

          2. Corneal pachymetry at the screening exam that is &lt;300 microns at the thinnest point in
             the eye(s) to be treated.

          3. Previous ocular condition (other than refractive error) in the eye(s) to be treated
             that may predispose the eye for future complications, for example:

               1. History of or active corneal disease (e.g., herpes simplex, herpes zoster
                  keratitis, recurrent erosion syndrome, acanthamoeba, etc.)

               2. Clinically significant corneal scarring in the CXL treatment zone that is not
                  related to keratoconus, or in the investigator's opinion, will interfere with the
                  cross-linking procedure.

          4. Pregnancy (including plan to become pregnant) or lactation during the course of the
             study

          5. A known sensitivity to study medications

          6. Patients with nystagmus or any other condition that would prevent a steady gaze during
             the CXL treatment or other diagnostic tests.

          7. Patients with a current condition that, in the physician's opinion, would interfere
             with or prolong epithelial healing

             -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Lubeck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arbor Center for Eye Care</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Lubeck, MD</last_name>
    <phone>708-249-1026</phone>
    <email>dr.lubeck@arboreyecare.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arbor Center for Eye Care</name>
      <address>
        <city>Orland Park</city>
        <state>Illinois</state>
        <zip>60467</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>David Lubeck, MD</last_name>
      <phone>708-249-1026</phone>
      <email>dr.lubeck@arboreyecare.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 22, 2020</study_first_submitted>
  <study_first_submitted_qc>January 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

